Industry News

• ADMA Biologics provides regulatory update for BIVIGAM® ADMA Biologics announces receipt of FDA communication stating the FDA considers the Company’s response to the agency’s information request related to the PAS submission a major amendment. As a result, the FDA will require an additional two months to complete their review of the PAS.
  October 11, 2018

More...